| Name | Title | Contact Details |
|---|---|---|
Catherine Lee |
Senior Vice President and General Counsel | Profile |
Akaza Research is a Waltham, MA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Cytek Biosciences Inc. is a leading manufacturer and supplier of flow cytometry products and services. Cytek`s compact, affordable instruments and wide ranging support offerings are used by researchers and clinicians all over the world. Flow cytometry is a powerful analytical tool used for identifying and quantifying cellular characteristics on a cell-by-cell basis up to tens of thousands of cells per second. This technology is used in research and clinical studies with various biomedical and therapeutic applications such as investigating the role of the body`s immune system in fighting cancer, diagnosing leukemia and lymphoma, and detecting minimal residual disease in organ transplant patients. Flow cytometry has many advantages over traditional microscopy since it enables the analysis of a greater number of cells in a fraction of the time. At Cytek, we are focused on accelerating the adoption of flow cytometry for one simple reason: to fuel scientific discovery. We have leveraged our highly experienced, best-in-the-business team to bring forth an innovative new class of flow cytometry solutions. These solutions deliver deep biological insights at an affordable price, provide high-end capabilities, and bring simplified workflows to more researchers than ever before. As a company, we also seek to maintain high ethical standards and a culture that values honesty, integrity and transparency in all that we do. Company decisions are driven by what is right for scientific discovery and customer support. We are committed to our employees, to the environment in which we live and to the communities we serve worldwide. Cytek is headquartered in Fremont, California with branch offices and distribution channels across the globe.
Sapphire Biotech, Inc.`s diagnostic tool is being used to study the company`s enzyme biomarker to detect pancreatic cancer earlier than circulating tumor cells.
Oxford Nanopore Technologies aims to disrupt the paradigm of biological analysis. Our technology and commercial model has already opened up DNA analysis to researchers who previously had no direct access to sequencing technologies, freeing them up to perform analyses in their own labs, in real time or in the field. Over time, the technology will continue to improve, new form factors of the technology will be introduced and workflows will be further simplified by new preparation techniques or analysis workflows. This technology pathway is designed to enable the analysis of any living thing, by any person, in any environment. Oxford Nanopore has developed the worlds first and only nanopore DNA sequencer, the MinION. The MinION is a portable, real time, long-read, low cost device that has been designed to bring easy biological analyses to anyone, whether in scientific research, education or a range of real world applications such as disease/pathogen surveillance, environmental monitoring, food chain surveillance, self-quantification or even microgravity biology. Commercially available since 2015, the MinION is in use by a thriving community of scientists in >50 countries, where it is enabling myriad applications within the traditional laboratory environment and in the field. Nanopore sensing technology is fully scalable. The GridION X5 is a desktop device that includes compute module and the ability to run up to five MinION Flow Cells. The the high-throughput/sample number PromethION is currently being released in the PromethION Early Access Programme (PEAP). Oxford Nanopore is focused on making DNA based analyses easy enough for any user and so we are working to simplify the sample preparation and data analysis processes. For sample preparation this includes a 5-10 minute sample prep kit, and VolTRAX (in development), a rapid, programmable, portable, disposable sample preparation device designed to prepare DNA for addition to a nanopore sequencing device.
Kurome Therapeutics is developing therapies that target cancer cells that have co-opted immune signaling pathways in order to avoid destruction by traditional therapeutic agents and subvert adaptive resistance mechanisms.